Heart Valves Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Region Forecast 2020-2031

Heart Valves Market size was valued at US$ 11.2 billion in 2024 and is expected to reach US$ 21.5 billion by 2031, growing at a significant CAGR of 9.8% from 2025-2031. The global market for artificial heart valves comprises mechanical components, typically made of durable materials such as titanium or carbon. These valves are surgically implanted to replace damaged or diseased natural heart valves, restoring normal blood flow through the heart. A prominent trend in the mechanical heart valve market is the increasing adoption of transcatheter heart valve replacement (TAVR) procedures. TAVR is a minimally invasive technique that offers a less invasive alternative to open-heart surgery for valve replacement.

The growing preference for TAVR procedures is driven by shorter recovery times, reduced hospital stays, and lower risk of complications, thereby fueling the demand for mechanical heart valves compatible with this technique. An opportunity in the mechanical heart valve market lies in emerging economies due to the rising prevalence of cardiovascular drugs diseases and increasing demand for advanced cardiac care. Additionally, technological advancements such as the development of sutureless mechanical heart valves and the integration of bioengineering principles hold promise for improved valve durability, reduced complications, and enhanced patient outcomes, presenting further opportunities for market growth. The mechanical heart valve market is witnessing a trend towards transcatheter heart valve replacement procedures, while opportunities lie in emerging economies and technological advancements for enhanced valve performance.

Key Developments:

• In January 2023, Medtronic and Edwards Lifesciences announced a collaboration to develop and commercialize a new mechanical heart valve. The valve, which is still in development, is designed to be more durable and less likely to cause blood clots than traditional mechanical heart valves.
• In February 2023, Boston Scientific and JenaValve announced a collaboration to develop and commercialize a new mechanical heart valve. The valve, which is still in development, is designed to be easier to implant than traditional mechanical heart valves.